Introduction {#s1}
============

Magnesium plays an important role in many cellular processes, including energy metabolism, DNA replication, RNA transcription and protein synthesis \[[@SFV081C1], [@SFV081C2]\]. Consequently magnesium homeostasis, which depends on magnesium uptake in the intestine, magnesium storage in bone and magnesium excretion in the kidney, needs to be strictly controlled. Several rare inherited diseases due to renal magnesium loss including autosomal dominant and autosomal recessive hypomagnesaemias have been described \[[@SFV081C2]--[@SFV081C4]\]. Hypomagnesaemia is usually defined as plasma magnesium levels \<0.7 mM. Identification of the genes and their encoded proteins involved in the pathogenesis of these diseases has contributed greatly to our knowledge of epithelial magnesium transport in the kidney.

In 1972, Michelis *et al.* \[[@SFV081C5]\] reported clinical data from two siblings with hypomagnesaemia, decreased bicarbonate threshold, distal renal tubular acidosis, nephrocalcinosis, polyuria and convulsions. Subsequently, similar cases were described showing that the patients also had hypercalciuria, nephrocalcinosis, progressive decline of renal function and, sometimes, severe ocular defects \[[@SFV081C6]--[@SFV081C10]\]. In these patients, the hypomagnesaemia and hypercalciuria were resistant to magnesium oral supplementation and thiazide treatment, respectively. This renal tubulopathy was named 'familial hypomagnesaemia with hypercalciuria and nephrocalcinosis' (FHHNC) \[[@SFV081C10]\]. Rodríguez-Soriano *et al*. \[[@SFV081C8]\] were the first to suggest that FHHNC was caused by a defect in magnesium and calcium reabsorption in the thick ascending limb (TAL) of Henle\'s loop, the main nephron segment for paracellular reabsorption of these two cations \[[@SFV081C11], [@SFV081C12]\].

Using a positional cloning method, Simon *et al.* \[[@SFV081C13]\] analyzed 12 families with FHHNC and identified a gene, *PCLN1* (now described as *CLDN16*), associated with the disorder. A few years later, Konrad *et al.* \[[@SFV081C14]\] studied a group of FHHNC patients, also affected with severe ocular defects and lacking mutations in *CLDN16*, and identified a second gene, *CLDN19*, linked to the disease. *CLDN16* and *CLDN19* encode the tight-junction (TJ) proteins claudin-16 and claudin-19, respectively, which are expressed in the TAL, interact with each other and play a key role in regulating the paracellular transport of magnesium and calcium \[[@SFV081C15]\]. During the last decade there have been significant advances in the pathophysiology of FHHNC. The current knowledge of clinical and molecular features of this disease is the focus of the present review.

Clinical characteristics {#s2}
========================

FHHNC \[type 1, Online Mendelian Inheritance in Man (OMIM) \#248250\] is a rare autosomal recessive tubular disease characterized by excessive renal magnesium and calcium excretion \[[@SFV081C8], [@SFV081C10]\]. Patients develop hypomagnesaemia, hypercalciuria and bilateral nephrocalcinosis and their clinical course is often complicated by the development of chronic renal failure. Hypomagnesaemia may disappear with the deterioration of the glomerular filtration rate (GFR) due to a decline in filtered magnesium. Furthermore, patients usually present with recurrent urinary tract infections, nephrolithiasis, polyuria, polydipsia and/or failure to thrive \[[@SFV081C8], [@SFV081C10], [@SFV081C16]--[@SFV081C18]\]. Presentation with clinical traits of FHHNC usually occurs early in childhood or before adolescence. Many patients show a marked decline in GFR at the time of diagnosis, and about one-third of them progress to chronic renal failure during adolescence. Problems associated with acute hypomagnesaemia, such as convulsions and muscular tetany, are less common. These features differentiate FHHNC from other inherited types of renal hypomagnesaemia (Table [1](#SFV081TB1){ref-type="table"}). Other biochemical anomalies consist of elevated serum parathyroid hormone (PTH) levels before the onset of chronic renal failure, incomplete distal tubular acidosis, hyperuricaemia and hypocitraturia \[[@SFV081C17]\]. It should be emphasized that the high serum levels of PTH observed in FHHNC patients contrast with the normal or reduced PTH levels associated with hypomagnesaemia \[[@SFV081C2]\]. This fact seems counterintuitive since magnesium deficiency can suppress PTH secretion. Ocular abnormalities, mainly severe myopia, macular colobomata and nystagmus, have been reported for a subset of patients \[[@SFV081C10], [@SFV081C14], [@SFV081C19]\]. This disease form is known as FHHNC with severe ocular involvement (type 2, OMIM \#24819). Table 1.Characteristics of FHHNC and other inherited types of renal hypomagnesaemiaDiseaseMutated gene (protein)Pattern of inheritanceSerum Mg^++^Urine Mg^++^Serum Ca^++^Urine Ca^++^Renal failureOther symptomsFHHNC type 1*CLDN16*\
(claudin-16)AR↓↑--↑+^a^NephrocalcinosisFHHNC type 2*CLDN19*\
(claudin-19)AR↓↑--↑+^a^Nephrocalcinosis, severe ocular defects^b^Gitelman syndrome*SLC12A3*\
(NCC)AR↓↑--↓--Muscle weakness, tetany, hypokalaemia, chondrocalcinosisHypomagnesaemia with secondary hypocalcaemia*TRPM6*\
(TRPM6)AR↓↑↓----Tetany, muscle spams, mental retardationIsolated dominant hypomagnesaemia*FXYD2*\
(Na^+^/K^+^-ATPase\
γ subunit)AD↓↑--↓--ConvulsionsIsolated recessive hypomagnesaemia*EGF*\
(EGF)AR↓↑------Tetany, mental retardation[^1][^2][^3]

Genetics {#s3}
========

Sixteen years ago Simon *et al.* \[[@SFV081C13]\] identified the *CLDN16* gene, which is linked to chromosome 3q, and found the first pathogenic mutations in patients with FHHNC from several countries. *CLDN16* encodes the TJ protein claudin-16. To date, \>50 *CLDN16* pathogenic mutations have been reported, including mainly missense mutations, and also nonsense mutations, splice site mutations and small deletions \[[@SFV081C13], [@SFV081C17]--[@SFV081C36]\]. The mutations are found in either a homozygous or compound heterozygous state and are spread over the five exons of the *CLDN16* gene. In the claudin-16 protein, most missense mutations are located in or near the four transmembrane domains, in the two extracellular segments and in the carboxy-terminal cytoplasmic region. Patients from Germany or Eastern European countries show a common *CLDN16* mutation, L151F, which is due to a widespread founder effect \[[@SFV081C17]\]. This mutation is located in the carboxy terminus of the first extracellular segment of claudin-16. In contrast, patients from North Africa frequently show another founder mutation, A139V, also affecting the first extracellular segment \[[@SFV081C19]\].

A second locus for FHHNC was mapped on chromosome 1p34.2 and three pathogenic mutations were identified in the *CLDN19* gene of patients who lacked mutations in *CLDN16* and showed severe ocular defects \[[@SFV081C14]\]*. CLDN19* encodes claudin-19, another member of the claudin family. Up to now, 17 different *CLDN19* pathogenic mutations have been identified \[[@SFV081C14], [@SFV081C19], [@SFV081C37]--[@SFV081C41]\]. These include mostly missense mutations located in exons 1--4 and a few nonsense mutations and large or small deletions. Missense mutations are found in the first extracellular segment or in the first three transmembrane domains of claudin-19. The majority of patients present homozygous mutations and a few are compound heterozygous. A founder effect has been indicated for the recurrent G20D mutation in Spanish and French families \[[@SFV081C14], [@SFV081C19], [@SFV081C37]\]. Recently a Mexican family of Spanish origin with three FHHNC-affected sisters homozygous for this mutation was reported, which suggests a remote common ancestor \[[@SFV081C42]\].

Konrad *et al.* \[[@SFV081C31]\] have established a phenotype--genotype correlation with regard to renal failure progression in FHHNC patients with *CLDN16* mutations. They have studied a cohort of 71 affected individuals and found that patients with loss-of-function mutations in both alleles exhibit a younger age at the presentation of FHHNC symptoms and a faster decline in renal function when compared with those bearing at least one mutation with partial function. These data suggest that the presence of at least one *CLDN16* allele with partial function is enough to predict a milder clinical phenotype. On the other hand, there are phenotypic differences between FHHNC patients with the same mutation. Most patients with *CLDN19* mutations develop disease symptoms during the first 2 years of life, but some may remain asymptomatic until the second decade of life \[[@SFV081C37], [@SFV081C43]\]. Phenotypic variability has been shown even in families with affected siblings harbouring the same *CLDN16* or *CLDN19* homozygous mutation \[[@SFV081C34], [@SFV081C42]\]. These differences suggest the likely contribution of epigenetic factors or other unknown genetic modifiers \[[@SFV081C37], [@SFV081C43]\].

*CLDN16* mutations that cause FHHNC can alter intracellular trafficking of claudin-16 or disturb its capacity to facilitate paracellular magnesium transport. Several claudin-16 mutants, such as R149L, G162V, L167P, G233D, S235P and S235F, are retained in the endoplasmic reticulum (ER) and are subjected to proteasomal degradation \[[@SFV081C25]\], while others accumulate in the Golgi complex (R149X, L151W and L151F) or are delivered to lysosomes (M71T, G191R and T303R) \[[@SFV081C22], [@SFV081C25], [@SFV081C31]\]. However, other mutants, including G88E, S110R, R114Q, H141D, L145P, L151W, G198A, R216C and G227R, are properly targeted to the TJ but show a complete or partial loss of function \[[@SFV081C25], [@SFV081C31]\]. In addition, Hou *et al.* \[[@SFV081C38]\] have shown that some *CLDN16* mutations, comprising L145P, L151F, G191R, A209T and F232C, prevent claudin-16/claudin-19 interactions. *CLDN19* mutations also have different consequences. Claudin-19 proteins encoded by mutations G20D and Q57E have trafficking defects \[[@SFV081C25], [@SFV081C38]\]; mutant G20D is confined to the ER, consistent with a defect of the normal signal peptide sequence of this protein, whereas mutant Q57E is found in the apical membrane with a diffuse pattern. Both mutations result in complete loss of claudin-19 function. Mutants L90P and G123R are localized in the TJ and cause partial loss of claudin-19 function \[[@SFV081C38]\]. These two mutations severely affect heteromeric interactions with claudin-16.

An understanding of the molecular mechanism by which *CLDN16* and *CLDN19* mutations cause FHHNC might provide novel alternatives for therapeutic intervention \[[@SFV081C44]\]. For instance, Müller *et al.* \[[@SFV081C23], [@SFV081C24]\] have shown that surface expression of several retained claudin-16 mutants could be improved by inhibiting endocytosis or using pharmacological chaperones. Moreover, the consequences of presumed missense mutations at the level of mRNA should be evaluated. We have found that two *CLDN16* missense mutations, R149L and G198A, can alter pre-mRNA splicing, resulting in defective mRNAs \[[@SFV081C45]\].

Claudin-16 and claudin-19 proteins {#s4}
==================================

Claudins are members of a family of 28 tetraspan membrane proteins that are found in TJs of epithelia and endothelia \[[@SFV081C15], [@SFV081C46], [@SFV081C47]\]. They form strands that mediate cell adhesion and function as both paracellular barriers and selective ion channels regulating the flow of ions and solutes between the luminal and basolateral spaces (Figure[ 1](#SFV081F1){ref-type="fig"}). Expression studies have indicated that claudin-16 functions predominantly as a pore-forming claudin increasing permeability to cations, whereas claudin-19 performs mainly as a barrier-forming claudin decreasing permeability to anions \[[@SFV081C48], [@SFV081C49]\]. Claudin proteins consist of four transmembrane domains (TM1--4), two extracellular segments (ECS1 and ECS2), amino- and carboxy-terminal cytoplasmic tails and a short cytoplasmic loop (Figure[ 2](#SFV081F2){ref-type="fig"}). Research studies on several claudins have suggested that ECS1 contains the ion selectivity filter while ECS2 is involved in claudin--claudin interactions \[[@SFV081C50]--[@SFV081C52]\]. Recently Suzuki *et al.* \[[@SFV081C53]\] reported the first crystal structure of a mammalian claudin (claudin-15), providing structural information on this family of TJ proteins. The structure showed that the four transmembrane segments form a tight four-helix package and that sections of the two extracellular segments form a domain with a beta-sheet structure. This palm-shaped domain is likely to contribute to trans-interactions between claudin molecules of adjacent cells, resulting in the formation of paracellular channels \[[@SFV081C54]\]. A disulphide bridge between two cysteine residues located in the first extracellular segment stabilizes the beta-sheet structure \[[@SFV081C53]\]. These cysteine residues are highly conserved among all members of the claudin family \[[@SFV081C15]\]. In addition, ECS1 contains a conserved glycine-leucine-tryptophan motif that also seems to contribute to stabilization of the appropriately folded ECS1 structure \[[@SFV081C55]\]. At the end of ECS1 there is a short extracellular helix (ECH) that links to TM2. Fig. 1.Schematic representation of tight junctions and putative location of claudin-16 and claudin-19. (**A**) TJs are the most apical intercellular junctions in epithelial cells of the nephron. They are composed of multiprotein complexes that include mainly claudins, occludin and the junctional adhesion molecules. (**B**) These protein components are arranged like beads on a string that span the adjacent membranes of each TJ. (**C**) Claudin-16 and claudin-19 are mainly found in TJs of epithelial cells of the TAL. They interact with each other, generating cation-selective pores. Fig. 2.Membrane model of claudins. The conserved structural features of claudins, four transmembrane domains (TM1--4), extracellular segments (ECS1 and ECS2) and ECH, are shown.

The intracellular amino terminus of claudins is usually very short, although claudin-16 could be an exception. The human *CLDN16* mRNA has two potential in-frame start codons that may produce a short and a long protein isoform. The difference between them would be only within the intracellular amino termini (3 and 73 amino acids, respectively), and it is still a matter of discussion whether the long version exists under physiological conditions \[[@SFV081C48], [@SFV081C56]\]. Although the two isoforms could exist in kidney cells, some findings support the hypothesis that the second start codon is the real translation start site \[[@SFV081C17], [@SFV081C48]\]. The intracellular carboxy-terminal tail of claudins seems to be involved in exit from the ER and trafficking to the TJ \[[@SFV081C57]\]. It contains phosphorylation and palmitoylation sites that seem to regulate the localization of claudins and the barrier properties of TJs \[[@SFV081C58]\]. At the end of this carboxy terminus there is usually a PDZ domain-binding motif that can interact with PDZ domains of TJ scaffolding/adapter proteins including ZO-1, ZO-2 and ZO-3 \[[@SFV081C59], [@SFV081C60]\]. These adaptor proteins directly or indirectly bind actin and therefore attach the TJ within the cytoskeleton. Mutation T303R in the carboxy terminus of claudin-16 results in inactivation of the PDZ domain-binding motif \[[@SFV081C22]\]. The mutant protein fails to interact with ZO-1 and is misdirected to the lysosomes for degradation. Thus the association between claudin-16 and ZO-1 is required for proper localization of claudin-16 in the TJ.

The expression pattern of claudins is tissue specific and most tissues express many claudins, which can interact with other claudin molecules to form the TJ strands. Claudin-16 is mainly expressed in the kidney, and in the nephron it is selectively expressed in TJs of renal epithelial cells of the TAL \[[@SFV081C13]\]. Expression of claudin-19 has been detected in the kidney, nervous system and retina \[[@SFV081C13], [@SFV081C61], [@SFV081C62]\]. Along the nephron, claudin-19 is expressed together with claudin-16 mainly in the TAL \[[@SFV081C38], [@SFV081C63], [@SFV081C64]\]. In peripheral neurons, claudin-19 is found in TJ-like structures of Schwann cells \[[@SFV081C65]\]. Claudin-19-deficient mice present peripheral neuropathy that might be attributed to deficient electrophysiological sealing of Schwann cells \[[@SFV081C65]\].

Pathophysiology {#s5}
===============

The first inherited disorder of claudins to be identified was FHHNC \[[@SFV081C13]\]. It was then established that mutations in claudin-16 (then *PCLN1*) lead to renal loss of magnesium and calcium. These initial discoveries indicated that claudin-16 was involved in the formation of a cation-selective TJ pore for the reabsorption of magnesium and calcium in the TAL. This segment of the nephron is where ∼60% of the filtered magnesium and 20% of the filtered calcium are recovered \[[@SFV081C11], [@SFV081C12]\]. The selective transport of magnesium and calcium in the TAL occurs through a paracellular pathway that is dependent on the lumen-positive transepithelial voltage generated by the activity of both the Na^+^--K^+^--2Cl^−^ co-transporter (NKCC2) and the renal outer medullary potassium (ROMK) channel at the apical membrane (Figure[ 3](#SFV081F3){ref-type="fig"}). Using claudin-16 pathogenic mutants and a cell model, Hou *et al.* \[[@SFV081C48]\] later found that claudin-16 just moderately enhanced magnesium permeability but greatly increased transepithelial Na^+^ permeability. This indicated that instead of acting as a magnesium channel, claudin-16 regulates the transepithelial voltage gradient, increasing paracellular Na^+^ permeability. The same group generated *Cldn16* knockdown (KD) mice that presented hypomagnesaemia, hypercalciuria, hypermagnesuria and nephrocalcinosis, a comparable phenotype to that of FHHNC patients \[[@SFV081C66]\]. Fig. 3.Paracellular reabsorption of magnesium and calcium in the TAL of Henle\'s loop. This transport depends on the lumen-positive electrical potential established by the transcellular reabsorption of other cations and anions. Reabsorption of Na^+^, K^+^ and Cl^−^ through the apical membrane occurs via the NKCC2 co-transporter. Na^+^ and Cl^−^ leave the epithelial cell through the Na^+^/K^+^-adenosine 5′-triphosphatase (ATPase) and the ClC-Kb channel at the basolateral membrane, respectively. K^+^ is excreted to the lumen by the ROMK channel. The backflow of Na^+^ through the paracellular channel, as a consequence of diminishing luminal Na^+^ concentrations, is an additional contributor to the lumen-positive voltage that forces magnesium and calcium reabsorption. Claudin-16 and claudin-19 facilitate the paracellular transport of magnesium and calcium. Activation of CaSR by extracellular calcium upregulates claudin-14, which in turn interacts with the claudin-16/claudin-19 complex and inhibits its cation permeability.

On the other hand, *CLDN19* mutations severely reduced Cl^−^ permeability, indicating that claudin-19 acts as a barrier in the TJ \[[@SFV081C38], [@SFV081C49]\]. *Cldn19* KD mice also developed FHHNC features, including hypomagnesaemia, hypercalciuria and hypermagnesuria \[[@SFV081C63]\]. siRNA knockdown of *Cldn19* expression causes a loss of claudin-16 from TJs in the TAL, while siRNA knockdown of *Cldn16* produces an analogous result on claudin-19. Both claudin-16- and claudin-19-depleted TJs show normal barrier function but defective ion selectivity \[[@SFV081C63]\]. These data suggested that a heteromeric caludin-16--claudin-19 interaction is needed for assembling of the complex into the TJ structure and generating the cation-selective paracellular pathway \[[@SFV081C38]\]. On the other hand, some *CLDN16* and *CLDN19* mutations disturb this interaction, implying a function in the TAL for claudin interaction in the development of FHHNC \[[@SFV081C38]\]. However, in retinal pigment epithelium, claudin-19 is expressed and functional in the absence of claudin-16 \[[@SFV081C67]\].

Alterations in extracellular calcium seem to affect the transport of calcium, magnesium and other ions in the TAL. The calcium/magnesium-sensing receptor (CaSR), highly expressed in the TAL, has been known to play an essential role in regulating divalent cation reabsorption in this segment of the nephron \[[@SFV081C68]\]. However, the precise role of CaSR is not entirely comprehended. Stimulation of CaSR by high concentrations of extracellular calcium may result in inhibition of the electrolyte transport handled by NKCC2 and ROMK, reduction in the lumen-positive electrical potential and, consequently, increased urinary excretion of magnesium and calcium. Nevertheless, recent evidence indicates that the principal task of CaSR in the TAL is to control paracellular permeability via regulation of claudin-14. This protein, encoded by *CLDN14*, is found mainly in the TAL and therefore it is also considered to be involved in divalent cation transport \[[@SFV081C69]\]. A genome-wide association analysis recognized *CLDN14* as a main risk factor for hypercalciuric nephrolithiasis \[[@SFV081C70]\]. Pathogenic mutations in this gene cause autosomal recessive deafness in children \[[@SFV081C71]\]. Hou *et al.* \[[@SFV081C69]\] have elegantly shown that claudin-14 interacts with claudin-16, repressing the cation selectivity of the heteromeric claudin-16/claudin-19 complex. Accordingly, under high calcium dietary conditions, *Cldn14* knockout (KO) mice progress to hypermagnesaemia, hypomagnesuria and hypocalciuria, the opposed phenotype to that of *Cldn16* KD mice \[[@SFV081C69]\]. On the other hand, transgenic mice overexpressing claudin-14 selectively in the TAL epithelium of the kidney present the FHHNC phenotype \[[@SFV081C72]\]. The same authors determined that the mechanism by which calcium regulates claudin-14 is through microRNA-based repression of *CLDN14* expression. Two kidney-specific microRNAs (miR-9 and miR-374) bind to the 3′-untranslated region of the *CLDN14* mRNA, repress its translation and induce its decay \[[@SFV081C69]\]. Extracellular calcium, through activation of CaSR, reduces the expression levels of these microRNAs, thus stimulating claudin-14 and preventing claudin-16/claudin-19-facilitated divalent cation reabsorption (Figure[ 3](#SFV081F3){ref-type="fig"}), which results in hypercalciuria \[[@SFV081C72]--[@SFV081C74]\]. These findings have encouraged the pursuit of therapeutic alternatives to reduce urinary calcium excretion. Recently, Gong *et al*. \[[@SFV081C75]\] showed that treatment with histone deacetylase (HDAC) inhibitors stimulates transcription of the two claudin-14 targeting microRNAs, repressing claudin-14 expression and reducing renal calcium excretion specifically in the TAL.

As mentioned before, FHHNC patients usually develop chronic renal failure, which is correlated with progressive tubulointerstitial nephritis; however, its pathophysiology is uncertain. Although it has been suggested that renal failure in FHHNC could be associated with the hypercalciuria and nephrocalcinosis present in these patients \[[@SFV081C10]\], a proper correlation has not been found. Recent findings have revealed a previously unidentified mechanism for crystal nephropathies and progression of chronic kidney disease (CKD) \[[@SFV081C76], [@SFV081C77]\]. This mechanism involves activation of the inflammasome, a high-molecular-weight enzymatic complex that triggers pro-inflammatory cytokine production in response to infection and tissue injury \[[@SFV081C78]\]. The most exhaustively characterized inflammasome is the NLRP3 (or NALP3) inflammasome, which seems to be involved in the pathogenesis of many renal diseases and their complications. NLRP3-mediated inflammasome activation could also initiative CKD in hereditary forms of crystal nephropathies like FHHNC. Although studies with several animal models have indicated that inhibition of the NLRP3 inflammasome reduces the progression of renal injury, additional research will be needed to establish if this could represent a therapeutic possibility for treating FHHNC or other renal tubulopathies. Moreover, it has been hypothesized that claudin-16 could also be implicated in tubular cell proliferation and differentiation \[[@SFV081C79]\]. This is supported by the phenotype of Japanese Black cattle with homozygous claudin-16 gene deletions, which shows renal failure due to interstitial nephritis \[[@SFV081C80], [@SFV081C81]\]. Nevertheless, another study argues that renal dysplasia may be unrelated to the absence of claudin-16 in cattle \[[@SFV081C82]\].

Diagnosis {#s6}
=========

Several hereditary magnesium transport diseases have been described and their associated genes have been identified \[[@SFV081C3], [@SFV081C4]\]. Their clinical characteristics, biochemical data and mode of inheritance can in many cases be used to distinguish them \[[@SFV081C3], [@SFV081C4]\]. In FHHNC, these characteristics include hypomagnesaemia, hypercalciuria, normocalcemia, hypermagnesuria, bilateral nephrocalcinosis, renal failure, autosomal recessive mode of inheritance and, in FHHNC type 2, ocular abnormalities such as severe myopia, macular colobomata and nystagmus (Table [1](#SFV081TB1){ref-type="table"}). As with other traits of FHHNC, the ocular defects are generally present at diagnosis early in childhood or before adolescence \[[@SFV081C19], [@SFV081C37], [@SFV081C43]\]. It should be noted that normal serum levels of magnesium do not exclude FHHNC \[[@SFV081C37], [@SFV081C83]\]. In case of normomagnesaemia, the fractional excretion values of magnesium can be valuable for diagnosis \[[@SFV081C83]\]. Because of the autosomal recessive mode of inheritance, many FHHNC patients originate from populations with a high frequency of consanguineous marriages.

To confirm the clinical diagnosis in FHHNC patients it is necessary to identify a pathogenic mutation in both alleles of the *CLDN16* or *CLDN19* genes. Mutational analysis is carried out by sequencing the coding exons and flanking intronic regions of these two genes \[[@SFV081C19], [@SFV081C37], [@SFV081C84]\]. Quantitative multiplex polymerase chain reaction of short fragments can be used to detect deletions of exons. Taking into account the presence or absence of severe ocular defects, depending on the origin of the patient, it might be reasonable to begin the mutational analysis with a study of frequent disease-causing mutations. As mentioned earlier, *CLDN16* mutations L151F and A139V are recurrent in patients from Germany, Poland and the Czech Republic and North Africa, respectively \[[@SFV081C17]--[@SFV081C19], [@SFV081C31], [@SFV081C83]\], and *CLDN19* mutation G20D is very frequent among Spanish patients or patients with Spanish ancestors \[[@SFV081C14], [@SFV081C19], [@SFV081C37], [@SFV081C85]\]. Therefore the first genetic screening in patients of these populations should be testing for the presence of the respective recurrent mutations. Specific mutations can be analyzed by SNaPshot or by sequencing the corresponding exon.

It should be noted that FHHNC types 1 and 2 are very rare disorders and their population prevalence is unknown. Only ∼70 apparently unrelated families (∼100 patients) with a *CLDN16* causative mutation and 60 families (∼70 patients) with a *CLDN19* causative mutation have been described in the literature \[[@SFV081C84]\]. Nevertheless, this disease is probably underdiagnosed due to a lack of awareness. FHHNC families with pathogenic mutations in either gene should seek genetic counselling for carrier status, disease members or prenatal diagnosis.

Treatment {#s7}
=========

Like with other inherited rare disorders, modification of the primary genetic defects is not yet realistic. There is no specific treatment for this disease and there have been no clinical trials that may guide us toward a therapeutic option. Therapeutic approaches to regulate the claudin genes involved in renal calcium and magnesium transport have been lacking. Therefore the current therapy is basically supportive. FHHNC patients are given oral magnesium supplementation and thiazide diuretics to prevent the progression of nephrocalcinosis or nephrolithiasis, but neither treatment has had a considerable effect on the levels of urinary calcium or serum magnesium or on the deterioration of renal function \[[@SFV081C10], [@SFV081C17], [@SFV081C19], [@SFV081C37]\]. However, a recent study of 25 FHHNC patients in Poland argues that treatment with thiazides effectively reduced hypercalciuria in most cases \[[@SFV081C83]\]. Vitamin D deficit is common in patients with CKD and is a risk factor for secondary hyperparathyroidism. Therefore supplementation with active vitamin D is sometimes included in the treatment of FHHNC patients. In addition, a recent study indicates that maintaining normal vitamin D levels helps preserve kidney function in children with CKD \[[@SFV081C86]\]. However, vitamin D supplementation is occasionally a controversial aspect of treatment because it increases intestinal calcium absorption and urinary calcium excretion, which might enhance calcium-stone formation. Consequently some physicians may be reluctant to prescribe vitamin D therapy to patients with hypercalciuria. The only alternative for treatment of renal dysfunction in FHHNC is renal replacement therapy in end-stage renal disease patients. Calcium and magnesium excretion is normalized after transplantation and there is no recurrence of the disease. Severe myopia can be corrected with glasses, contact lenses, laser surgery or implanting artificial lenses. At present, there is no therapy for nystagmus or macular colobomata.

Conclusions and perspectives {#s8}
============================

Since the identification of the *CLDN16* gene and its association with FHHNC in 1999, there have been important advances in our knowledge of the pathogenesis of this disease. However, although the essential role of claudin-16, claudin-19 and claudin-14 in paracellular transport of magnesium and calcium in the TAL has been elucidated, much needs to be done in order to fully comprehend the pathophysiology of FHHNC. Undoubtedly the recent elucidation of the claudin-15 crystal structure will improve the molecular comprehension of paracellular barriers between epithelial cells.

Claudin-19 is expressed at high levels in the retina, but why mutations in this claudin cause ocular defects is still unknown. Claudin-19 is also expressed in peripheral neurons, and in fact *Cldn19* KO mice present peripheral neuropathy \[[@SFV081C65]\]. However, the function of claudin-19 in this part of the nervous system has not been determined. On the other hand, the possible contribution of epigenetic factors or genetic modifiers on the phenotypic variability observed in some patients with FHHNC has been suggested, but there are no studies addressing this question. We need to learn more in relation to the interactions of claudin-16, claudin-19 and claudin-14 with other factors and their potential signalling functions. In addition, further evaluation of the consequences of specific *CLDN16* and *CLDN19* mutations remains an area for further investigation that could deliver new therapeutic strategies.

For many years, the only available therapy for hypercalciuria has been through the use of diuretics such as thiazide and amiloride. Therapeutic approaches to regulate claudin function in renal calcium transport have been lacking. The recent discovery that claudin-14 is an inhibitory subunit of the claudin-16/claudin-19 complex has prompted the search for new therapeutic alternatives to reduce urinary calcium excretion relying on this pathway. This has led to the identification for a new approach based on HDAC inhibitors and microRNA regulation that seems promising for the treatment of hypercalciuric diseases.
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[^1]: ATPase, adenosine 5′-triphosphatase; AR, autosomal recessive; AD, autosomal dominant; NCC, Na**^+^**/Cl^−^ cotransporter; TRPM6, transient receptor potential channel malastatin member 6; EGF, epidermal growth factor.

[^2]: ^a^Chronic renal failure in infancy or early adolescence.

[^3]: ^b^Myopia, macular colobamata and nystagmus.
